en
E-mail us

Developability Assessment Services

Solid-State Characterization/FAST

Our Solid State Characterization Service, which is referred to as Focused Analytical Solids Testing (FAST), covers many routine analyses encountered during pharmaceutical development. The FAST concept is directly aligned with our goal of partnering with organizations instead of merely providing data.

pKa/LogP/LogD Measurements

Earlier than ever before in the development timeline, biotech can achieve a comprehensive understanding of their molecule's physicochemical properties. Using material-sparing automation, Crystal P...

Stability and Solubility Studies

Chemical and physical stability. The intent of the stability study is to evaluate the chemical and physical stability of the API in solution and solid-state. The solid-state evaluation will probe the pr...

In-Silico PBPK Modeling and Simulation

Crystal Pharmatech now provides Physiologically Based Pharmacokinetics (PBPK) simulation capability.

Developability Assessment


Understand your molecule, unlock its potential


The world needs new medicines and drug developers are racing to bring promising molecules to the market. However, drug development programs stall when:

         - Physicochemical properties of API form and formulation are uncertain

         - Lead compounds require quantifiable comparison

         - Form and formulation guesswork cause incoherent tox exposures


From lead optimization to First in Human (FIH), programs are at risk of hitting significant speed bumps if the physicochemical risks for API form and formulation are never evaluated.


Innovators need a strategic and cohesive approach to move their molecule to medicine.

 

Molecule to Medicine

The Mol2Med™ Developability Assessment is a dynamic, fit-for-purpose service that helps drug developers achieve a comprehensive understanding of their molecule's potential for development.


Mol2Med_Overview_Webpage_-_Design_Elements-01.png


With as little as 500mg of API and 4 weeks, Crystal Pharmatech offers a smarter path forward by:

         - Determining the key physicochemical properties of your compound(s)

         - Benchmarking according to industry standards

         - Providing a high-level approach for achieving most probable success in GLP Tox and FIH

 


Mol2Med_Overview_Webpage_-_Design_Elements-02.png

Look Before You Jump

Before you select a lead compound...

Before you conduct a salt screening...

Before you gavage with every possible vehicle...

Before moving to formulation...


You need to understand the key risks inherent to your molecule based on its physical properties.


Mol2Med_Overview_Webpage_-_Design_Elements-03.png


A full understanding of your molecule goes well beyond test results and raw data. Industry benchmarking builds upon decades of efforts and studies to predict in vivo performance.


Combined with AI-driven technologies and in silico capabilities, you will gain powerful insights to unlock your molecule's potential and make faster, smarter decisions forward.


Our Experience Becomes Your Competitive Advantage

Crystal Pharmatech R&D and Subject Matter Experts have decades of experience moving molecules to medicine.


We derive highly accurate data from novel API-sparing technologies. We run this data through in silico simulations, industry benchmarks, and Crystal Pharmatech experts to give our partners insights that will:

         - Expedite your development timeline

         - Minimize costs through a strategic scope of work

         - Maximize your molecule's likelihood of success in GLP Tox and FIHMol2Med_Overview_Webpage_-_Design_Elements-04.png



Our pathway offers specific next steps to reach all major milestones throughout your drug development program - from lead compound selection to formulation development.


Leading experts will ensure CMC is not limiting Tox and Phase I success while assessing later stage developability risks of API and drug product.


The cohesion between our solid-state and formulation experts ensures continuity and a goal-oriented approach throughout every stage of development.


                 


Want to Know More?

If you have any questions, we will always be happy to help. Feel free to contact us by telephone, mail or leave a message.
Address:
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.
Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303